SUS Stock Overview
Develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SUS from our risk checks.
Surgical Science Sweden AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr144.60 |
52 Week High | kr251.60 |
52 Week Low | kr118.80 |
Beta | 0.92 |
1 Month Change | -6.16% |
3 Month Change | -2.17% |
1 Year Change | -38.52% |
3 Year Change | -9.63% |
5 Year Change | 367.96% |
Change since IPO | 1,157.39% |
Recent News & Updates
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Recent updates
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Shareholder Returns
SUS | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | 3.1% | 1.5% | -0.9% |
1Y | -38.5% | -7.1% | 14.3% |
Return vs Industry: SUS underperformed the Swedish Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: SUS underperformed the Swedish Market which returned 14.3% over the past year.
Price Volatility
SUS volatility | |
---|---|
SUS Average Weekly Movement | 7.6% |
Medical Equipment Industry Average Movement | 7.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SUS has not had significant price volatility in the past 3 months.
Volatility Over Time: SUS's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 265 | Gisli Hennermark | www.surgicalscience.com |
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room.
Surgical Science Sweden AB (publ) Fundamentals Summary
SUS fundamental statistics | |
---|---|
Market cap | kr7.38b |
Earnings (TTM) | kr207.95m |
Revenue (TTM) | kr842.02m |
35.5x
P/E Ratio8.8x
P/S RatioIs SUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SUS income statement (TTM) | |
---|---|
Revenue | kr842.02m |
Cost of Revenue | kr264.50m |
Gross Profit | kr577.52m |
Other Expenses | kr369.57m |
Earnings | kr207.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | 4.08 |
Gross Margin | 68.59% |
Net Profit Margin | 24.70% |
Debt/Equity Ratio | 0% |
How did SUS perform over the long term?
See historical performance and comparison